AlbertF.LoBuglioMD
Oncology • Birmingham, ALProfessor, Medicine, University of Alabama School of Medicine
Are you Dr. LoBuglio?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 34 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1802 6th Ave S
Np 2556
Birmingham, AL 35233Phone+1 205-934-5077Fax+1 205-975-7428
Summary
- Dr. Albert LoBuglio, MD is an oncologist in Birmingham, Alabama. He is currently licensed to practice medicine in Alabama. He is a Professor at University of Alabama School of Medicine.
Education & Training
Boston University Medical CenterResidency, Internal Medicine, 1965 - 1967
UPMC Medical EducationResidency, Internal Medicine, 1963 - 1965- UPMC Medical EducationInternship, Transitional Year, 1962 - 1963
Georgetown University School of MedicineClass of 1962
Certifications & Licensure
AL State Medical License 1983 - 2015
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1974
Clinical Trials
- Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer Start of enrollment: 1999 Oct 01
- Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas Start of enrollment: 1999 Oct 01
Publications & Presentations
PubMed
- 9 citationsTBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormon...Christos Vaklavas, Brian S. Roberts, Katherine E. Varley, Nan Lin, Minetta C. Liu
Breast Cancer Research. 2020-02-18 - 11 citationsTrastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) InhibitionMonica E. Wielgos, Zhuo Zhang, Rajani Rajbhandari, Tiffiny S. Cooper, Ling Zeng
Molecular Cancer Therapeutics. 2018-03-28 - 103 citationsExpression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes.Andres Forero, Yufeng Li, Dongquan Chen, William E. Grizzle, Katherine L. Updike
Cancer Immunology Research. 2016-05-01
Press Mentions
Closing the GapNovember 3rd, 2022- Cancer Disparities Through the DecadesJune 10th, 2022
Personalized Medicine: UAB Breast Cancer Research Works Toward Focused TreatmentsOctober 6th, 2016
Grant Support
- Comprehensive Cancer Center Core Support GrantNational Cancer Institute1995–2003
- Novel Radioimmunotherapy For Ovarian CancerNational Cancer Institute2000–2002
- Targeted Immunotherapy ProgramNational Cancer Institute1999–2002
- Interferon Enhanced Intraperitoneal Radioimmunity For Ovarian CancerNational Center For Research Resources1997–2002
- Rituxan In Treatment Of Immune Thrombocytopenic PurpuraNational Center For Research Resources2000
- Idec-Y902b8 Radioimmunotherapy: Relapsed B Cell LymphomaNational Center For Research Resources2000
- Recombinant Vaccinia CEA (70DD) Vaccine In Low Tumor Burden Colorectal CancerNational Center For Research Resources1998–2000
- Onco Vax CL In Colorectal CancerNational Center For Research Resources1998–2000
- Imaging Trial Of 3622w94National Center For Research Resources1998–2000
- Renovation Of Space In Volker HallNational Center For Research Resources1999
- Bms191352 In Advanced CarcinomaNational Center For Research Resources1997–1999
- Recombinant Tumor Vaccine--CatbrmNational Cancer Institute1996–1999
- Core--Institutional ProtocolsNational Cancer Institute1996–1999
- Core--Developmental FundsNational Cancer Institute1996–1999
- Clinical Trials Of Biological Response Modifiers-Task ANational Cancer Institute1996–1999
- Safety And Pharmacokinetics Of 3622w94National Center For Research Resources1997
- Recombinant Vaccinia-Cea (70DD) Vaccine In Low Tumor Burden AdenocarcinomaNational Center For Research Resources1997
- Completion Of Shell Space For Genetics CenterNational Center For Research Resources1997
- Bms-182248(Br96-Doxorubicin Conjugate) In Patients With Advanced CarcinomaNational Center For Research Resources1997
- Recombinant Rv-Cea In Low Tumor Burden Adenocarcinoma Of The ColonNational Center For Research Resources1996
- R CEA Immunogen In Metastatic Adenocarcinoma Of The BreastNational Center For Research Resources1996
- Bms-182248 In Patients With Advanced CarcinomaNational Center For Research Resources1996
- Clinical Trials Of Biological Response ModifiersDivision Of Cancer Treatment1995–1996
- Tumor Vaccine CatbrmNational Cancer Institute1993–1995
- Monoclonal Antibodies And Other Targeting AgentsDivision Of Cancer Treatment1989–1994
- Cancer Center Core Support GrantNational Cancer Institute1985–1994
- Construction Grant For Rodent Barrier UnitNational Cancer Institute1992
- Human Immune Cytopenias--Monoclonal AntibodiesNational Institute Of Allergy And Infectious Diseases1989–1991
- Radiolabeled Chimeric Monoclonal Antibody (C-17-1a) Colon CancerNational Center For Research Resources1990
- Phase I 131-1 Lym-1 Patients With Diffuse Aggressive LymphomasNational Center For Research Resources1990
- IV 131I Labeled Chimeric Igg4 B72.3 In Advanced Colorectal CarcinomaNational Center For Research Resources1990
- Chimeric Monoclonal Anti-Gd2 Antibody 14.18 In Metastatic MelanomaNational Center For Research Resources1990
- Hematology Training ProgramNational Institute Of Diabetes And Digestive And Kidney Diseases1986–1988
- Human Immune Cytopenias-Studies With Monoclonal AntibodyNational Institute Of Allergy And Infectious Diseases1985–1988
- Melanoma Tumor Detection Using III Inlabeled Monoclonal Antibody Type 96.5National Center For Research Resources1985
- Colon Cancer Tumor Imaging Using Iii-Indium Labeled Monoclonal Antibody Zce 025National Center For Research Resources1985
- Core Facilites--Outpatient Nursing UnitNational Cancer Institute1985
- Cancer Center Core Support Grant (COMPREHENSIVE)National Cancer Institute1985
- Hematology Training ProgramNat Inst Of Arthritis, Diabetes, Digestive &Kidney Diseases1985
